Complaints Rising on Pharma Comparative Claim Violations

A sharp increase in exaggerated or misleading comparative claims in drug advertisements has the FDA analyzing the issue and considering guidance on it to help stop the violations. The number of problematic superiority and comparative claims in promotional materials doubled in fiscal 2012 compared with the previous year, Lisa Stockbridge, chief of CBER’s advertising and promotional labeling branch, said Oct. 1.
Washington Drug Letter